RxDoctor Payments Data

Cynthia Kurosky, PA

Medical · Smithfield, PANPI 1790261147

Payments from drug & device makers

$11,428in general payments, 2019–2025

Across 750 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • GSK$901
  • AstraZeneca$882
  • Boehringer Ingelheim$815
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$11,404100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,428 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$32,704
Medicare patients
117
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$101,462
TrulicityDulaglutide66$76,846
EliquisApixaban77$50,674
JardianceEmpagliflozin41$48,677
FarxigaDapagliflozin Propanediol41$42,596
MounjaroTirzepatide33$41,371
RybelsusSemaglutide13$25,159
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$18,318
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,621
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$7,660
ArexvyRsvpref3 Antigen/As01e/Pf13$4,148
Rosuvastatin Calcium189$2,523
Atorvastatin Calcium207$2,518
Humalog Kwikpen U-100Insulin Lispro18$2,393
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,524$126,62080 claims
Lilly USA, LLCTrulicity, Mounjaro$1,396$118,21799 claims
PfizerEliquis$585$50,67477 claims
Boehringer IngelheimJardiance$815$48,67741 claims
AstraZenecaFarxiga$882$42,59641 claims
GSKAnoro Ellipta, Trelegy Ellipta, Arexvy$901$40,08754 claims
Almatica Pharma LLCSertraline Hcl$14$1,320144 claims
AbbVieSynthroid$1,260$1,26446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Smithfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →